[]
Hawkins C.A., Mellanby J.H.: Piracetam potentiates the antiepileptic
action of carbamazepine in chronic experimental limbic epilepsy. Acta
Neurol Scand 1986; 74 (Suppl. 109): 117–121.
[]
Majkowski J.: Piracetam – ponowne spojrzenie. Przegląd piśmiennictwa
i doświadczenia własne. Epileptologia 2006; 14: 101–122.
[]
Steinborn B., Galas-Zgorzalewicz B.: Studies on the pharmacokinetics of
total and free valproate in mono- and bitherapy with carbamazepine in
epileptic children and adolescents. Folia Neuropathol 2002; 40: 97–100.
[]
Calliauw L., Marchau M.: Clinical trials of piracetam in disorders of
consciousness due to head injury. Acta Anaesthesiol Belg 1975; 26:
51–60.
[]
Gobert J.G.: Genese d’un medicament: le piracetam, metabolisation et
recherche biochimique. J Pharm Belg 1972; 27: 281–304.
[]
Gidal B.E., Baltés E., Otoul C., et al.: Effect of levetiracetam on the
pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of
data from randomized clinical trials. Epilepsy Res 2005; 64: 1–11.
[]
Patsalos P.N.: Drug Interactions with the Newer Antiepileptic Drugs
(AEDs)-Part 1: Pharmacokinetic and Pharmacodynamic Interactions
Between AEDs. Clin Pharmacokinet 2013; Jun 20.
[]
Tolou-Ghamari Z.: Antiepileptic drugs (AEDs) polypharmacy could lead
to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett
2012; 6: 207–212.
[]
Steinborn B.: Znaczenie badań farmakokinetycznych leków
przeciwpadaczkowych w leczeniu padaczki u dzieci i młodzieży.
Neurologia Dziecięca 2006; 15: 7–15.
[]
Sobaniec W., Sobaniec H., Sobaniec-Łotowska M.: Monitorowane
leczenie padaczki u dzieci. [w:] Postępy w Diagnostyce i Leczeniu
Chorób Układu Nerwowego u Dzieci. Wydawnictwo Bifolium, Lublin
2000, t. 2, 34–44.
[]
Johannessen Landmark C., Baftiu A., Tysse I., et al.: Pharmacokinetic
variability of four newer antiepileptic drugs, lamotrigine, levetiracetam,
oxcarbazepine, and topiramate: a comparison of the impact of age and
comedication. Ther Drug Monit 2012; 34: 440–445.
[]
Mondadori C., Schmutz M., Balcer V.: Synergistic effects of oxiracetam
and piracetam in combination with antiepileptic drugs. Acta Neurol
Scand 1986; 74 (Suppl. 109): 113–116.
[]
Claus J.J., Ludwig C., Mohr E., et al.: Nootropic drugs in Alzheimer’s
disease: symptomatic treatment with pramiracetam. Neurology 1991;
41: 570–574.
[]
Śmigielska-Kuzia J., Sobaniec W., Kułak W.: Evaluation of efficacy of
piracetam in add-on treatment of partial epilepsy in children. 3rd Europ.
Congr. Epilept., Edited by Majkowski J., Owczarek K., Zwoliński P.,
Monduzi Eitore, 1998, 427– 431.
[]
Custer K.L., Austin N.S., Sullivan J.M., et al.: Synaptic vesicle protein 2
enhances release probability at quiescent synapses. J Neurosci 2006;
26: 1303–1313.
[]
Sendrowski K., Sobaniec W.: New antiepileptic drugs – an overview.
Rocz Akad Med Bialymst 2005; 50 (Suppl 1): 96–98.
[]
Sendrowski K., Sobaniec W., Artemowicz B.: Rola kwasu gammaaminomasłowego
w drgawkach i padaczce. Epileptologia 1999; 1:
23–38.
[]
Ahmed A.H., Oswald R.E.: Piracetam defines a new binding site for
allosteric modulators of alpha-amino-3-hydroxy-5-methyl-isoxazolepropionic
acid (ampa) receptors. J Med. Chem 2010; 53: 2197–2203.
[]
Nickolson V.J., Wolthuis O.L.: Effect of the acquisition-enhancing
drug piracetam on rat cerebral energy metabolism. Comparison with
naftidrofuryl and methamphetamine. Biochem Pharmacol 1976; 25:
2241–2244.
[]
Malykh A.G., Sadaie M.R.: Piracetam and piracetam-like drugs: from
basic science to novel clinical applications to CNS disorders. Drugs
2010; 70: 287–312.
[]
Müller W.E., Eckert G.P., Eckert A.: Piracetam: novelty in a unique mode
of action. Pharmacopsychiatry 1999; 32 (Suppl 1): 2–9.
[]
Winblad B.: Piracetam: a review of pharmacological properties and
clinical uses. CNS Drug Rev. 2005; 11: 169–182.
[]
Śmigielska-Kuzia J., Sobaniec W., Kułak W., et al.: Ocena skuteczności
piracetamu w porównaniu z flunaryzyną w leczeniu migreny
i napięciowych bólów głowy u dzieci. Neurol Dziec 2002; 11: 45–58.
Scholar Google
PubMed